Stockscreener 앱 받기
1.90
5.47%
-0.11
시간 외 거래:
1.89
-0.01
-0.53%
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan
Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan
Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan
Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan
Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan
Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan
[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan
Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - AD HOC NEWS
Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView
Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance
Fate Therapeutics Appoints Laura Hamill to Board of Directors - GlobeNewswire
FATE Stock Price, Quote & Chart - ChartMill
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
FATE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $7.00 - GuruFocus
H.C. Wainwright reiterates Fate Therapeutics stock rating on SLE data By Investing.com - Investing.com Canada
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Fate Therapeutics Advances Off-the-Shelf CAR T-Cell Therapies for Autoimmune Diseases and Cancer – Clinical Pipeline and 2026 Updates - Minichart
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline - TipRanks
Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash - TradingView
Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028 - Stock Titan
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting - markets.businessinsider.com
Fate Therapeutics presents autoimmune therapy data at EULAR - Investing.com
Fate Therapeutics presents autoimmune therapy data at EULAR By Investing.com - Investing.com South Africa
Small lupus trial tests off-the-shelf CAR T with same-day discharge - Stock Titan
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Off-the-shelf FT836 shrinks tumors in colorectal cancer without conditioning chemo - Stock Titan
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting - Yahoo Finance
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? - Yahoo Finance
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
Fate Therapeutics Surges Over 10% as Biotech Sector Shows Signs of Life (FATE)Equity Put Call - newsline.com
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
FATE Q1 2026 Earnings: Narrows Loss Per Share, Stock Rises on Improved Bottom LineRevenue Growth Report - newsline.com
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com India
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo
Fate Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7%Earnings Growth Forecast - newsline.com
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan
Fate Therapeutics to present CAR T-cell data at medical conferences By Investing.com - Investing.com South Africa
Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider
Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com
Fate Therapeutics Announces Presentations at 2026 ASCO and - GlobeNewswire
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases - The Manila Times
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com India
[144] FATE THERAPEUTICS INC SEC Filing - Stock Titan
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - TradingView
1.27%
1.43%
자본화:
|
볼륨(24시간):